Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Babasola O Popoola"'
Autor:
Gordon J. S. Rustin, Richard Kaplan, Andrew Embleton-Thirsk, Matthew R. Sydes, Elizabeth Deane, Laura Farrelly, Babasola O Popoola, Mahesh K. B. Parmar, Jonathan A. Ledermann, Judith Parker, Stephen Townsend
Publikováno v:
Clinical Trials (London, England)
Background: The ICON6 trial (ISRCTN68510403) is a phase III academic-led, international, randomized, three-arm, double-blind, placebo-controlled trial of the addition of cediranib to chemotherapy in recurrent ovarian cancer. It investigated the use o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8a0153c341a04f57645d6b96f658b4
https://pubmed.ncbi.nlm.nih.gov/31347385
https://pubmed.ncbi.nlm.nih.gov/31347385
Autor:
Mark L. Bernstein, Andreas Wiener, Neyssa Marina, Jeremy Whelan, Katja Baust, Lars Hjorth, Gordana Jovic, Meriel Jenney, Patricia de Vos, Babasola O Popoola, Stefan S. Bielack, Mark Krailo, Gabriele Calaminus, Pancras C.W. Hogendoorn, Cristina Sauerland, Sigbjørn Smeland, Carmen Teske, Rajaram Nagarajan, Clara V Schweinitz, Matthew R. Sydes, Kiana Kreitz
Publikováno v:
JMIR Research Protocols
JMIR RESEARCH PROTOCOLS
JMIR Research Protocols, 8(9)
JMIR RESEARCH PROTOCOLS
JMIR Research Protocols, 8(9)
Background The quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aec4ec6eea1e1f63318e50f64e8e46e1
https://pubmed.ncbi.nlm.nih.gov/31573951
https://pubmed.ncbi.nlm.nih.gov/31573951
Autor:
Ann Marie Swart, Amit M. Oza, Jonathan A. Ledermann, Mahesh K. B. Parmar, Laura Farrelly, Antonio Gonzalez Martin, Gordon J. S. Rustin, Elizabeth Clark, Andrew C. Embleton, Hal W. Hirte, Richard Kaplan, Gordon C Jayson, Stanley B. Kaye, Babasola O Popoola, Michael Friedlander, Michelle Margaret Vaughan, Adrian Cook, Timothy J. Perren
Publikováno v:
Journal of Clinical Oncology. 35:5506-5506
5506 Background: ICON6 is a three-arm double-blind, placebo-controlled phase 3 trial of cediranib in platinum-sensitive relapsed ovarian cancer (NCT00532194). The primary analysis (Ledermann et al Lancet 2016) showed a significant (p < 0.0001), 2.3 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd12ed2fc52ccd65498aa4d995b42aee
https://doi.org/10.1200/jco.2017.35.15_suppl.5506
https://doi.org/10.1200/jco.2017.35.15_suppl.5506